UBS Group AG Trims Position in OR Royalties Inc. $OR

UBS Group AG decreased its holdings in shares of OR Royalties Inc. (NYSE:OR) by 36.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 346,499 shares of the basic materials company’s stock after selling 196,807 shares during the quarter. UBS Group AG owned about 0.19% of OR Royalties worth $12,263,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Assetmark Inc. purchased a new position in OR Royalties during the fourth quarter worth about $36,000. Caitlin John LLC purchased a new stake in OR Royalties in the 3rd quarter valued at about $78,000. Eagle Global Advisors LLC purchased a new stake in OR Royalties in the 3rd quarter valued at about $206,000. Merit Financial Group LLC acquired a new position in shares of OR Royalties during the 3rd quarter valued at about $215,000. Finally, Flow Traders U.S. LLC acquired a new position in shares of OR Royalties during the 3rd quarter valued at about $217,000. Hedge funds and other institutional investors own 68.52% of the company’s stock.

Analyst Upgrades and Downgrades

OR has been the topic of several research analyst reports. TD Securities reissued a “hold” rating on shares of OR Royalties in a research report on Monday, February 23rd. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $56.00 price target on shares of OR Royalties in a research report on Friday, April 10th. Canadian Imperial Bank of Commerce reaffirmed an “outperform” rating on shares of OR Royalties in a research note on Wednesday, February 4th. Zacks Research lowered shares of OR Royalties from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Finally, Wall Street Zen cut shares of OR Royalties from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 11th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $46.50.

OR Royalties Trading Down 2.3%

NYSE:OR opened at $38.30 on Friday. The firm’s fifty day simple moving average is $39.14 and its 200 day simple moving average is $38.30. OR Royalties Inc. has a twelve month low of $22.63 and a twelve month high of $48.06. The firm has a market capitalization of $7.18 billion, a price-to-earnings ratio of 28.58 and a beta of 0.71.

OR Royalties (NYSE:OR) last announced its quarterly earnings results on Wednesday, May 6th. The basic materials company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.06. The firm had revenue of $102.83 million during the quarter, compared to the consensus estimate of $103.27 million. OR Royalties had a return on equity of 15.10% and a net margin of 78.09%. On average, analysts predict that OR Royalties Inc. will post 1.38 earnings per share for the current year.

OR Royalties Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Tuesday, June 30th will be issued a dividend of $0.065 per share. This represents a $0.26 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Tuesday, June 30th. This is an increase from OR Royalties’s previous quarterly dividend of $0.06. OR Royalties’s dividend payout ratio (DPR) is 16.42%.

OR Royalties Company Profile

OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.